Biography

Patrick W. Sullivan joined Harrow as Head of Commercial in August 2025, bringing 25 years of commercial leadership experience across U.S. and global markets. A proven strategist and operator, he has deep expertise in commercialization planning, launch strategy, market development, go-to-market execution, and growth acceleration in specialty, rare, and complex diseases. His experience spans emerging biotechs, mid-sized firms, and global pharma. Before joining Harrow, Mr. Sullivan was Vice President of Marketing, Neurology Portfolio at Corium Therapeutics, where he led U.S. commercialization and launches in ADHD and dementia. Under his leadership, Azstarys® became the fastest-growing ADHD treatment, while Adlarity® introduced a novel transdermal delivery technology of Donepezil for Alzheimer’s disease. Previously, he served as Global Commercial Head and Executive Director at AstraZeneca, directing the launch of Evrenzo® (roxadustat), a first-in-class anemia therapy. This launch marked an industry milestone as the first novel MOA to debut in China ahead of the U.S. or EU, and Mr. Sullivan partnered with development teams to advance multiple new indications. Earlier in his career, he held leadership roles at Shire, Adolor, Novartis, and Bayer, consistently exceeding performance goals and earning multiple team and individual awards. Mr. Sullivan holds a B.S. in Business Administration from Widener University and is pursuing an Executive MBA in Healthcare Marketing at Saint Joseph’s University.